BioMarin Pharmaceutical (BMRN) vs Praxis Precision Medicines (PRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 76.9% versus a gain of 10.5%. Over five years, PRAX leads with a +19.5% price change compared with -31.0% for BMRN. BioMarin Pharmaceutical is the larger company by market cap ($11.70 billion vs $8.40 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | PRAX |
|---|---|---|
| Share price | $60.41 | $300.43 |
| Market cap | $11.70B | $8.40B |
| 1-day change | -1.64% | -3.37% |
| YTD return | +1.65% | +1.93% |
| 1-year return | +10.46% | +76.93% |
| 5-year return | -31.02% | +19.50% |
| Forward P/E | 9.60 | — |
| EPS (TTM) | $-0.10 | $-12.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | $0 |
| Revenue growth (YoY) | +12.87% | -100.00% |
| Net income (latest FY) | $348.90M | $-303.27M |
| Gross margin | 77.73% | — |
| Operating margin | 12.71% | — |
| Net margin | 10.83% | — |
| 52-week high | $70.98 | $392.70 |
| 52-week low | $49.26 | $167.32 |
| Distance from 52-week high | -14.89% | -23.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +49.48% | +124.49% |
| Average volume | 2.35M | 479.87K |
| Shares outstanding | 193.69M | 27.95M |
| Employees | 3,221 | 168 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed BMRN by 66.5 percentage points over the past year.
- BioMarin Pharmaceutical grew revenue faster in its latest fiscal year (+12.87% vs -100.00%).
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
BMRN vs PRAX FAQ
Which is bigger, BioMarin Pharmaceutical or Praxis Precision Medicines?
BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $11.70B compared with $8.40B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, BMRN or PRAX?
PRAX returned +76.93% over the past 12 months, compared with +10.46% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Are BioMarin Pharmaceutical and Praxis Precision Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.